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Fas ligand (FasL) exerts potent proapoptotic and proinflam-
matory actions on epidermal keratinocytes and has been impli-
cated in the pathogenesis of eczema, toxic epidermal necrolysis,
and drug-induced skin eruptions. We used reconstructed
human epidermis to investigate the mechanisms of FasL-in-
duced inflammatory responses and their relationships with
FasL-triggered caspase activity. Caspase activity was a potent
antagonist of the pro-inflammatory gene expression triggered
byFasLprior to theonsetof cell death. Furthermore,we found that
FasL-stimulated autocrine production of epidermal growth factor
receptor (EGFR) ligands, and the subsequent activation of EGFR
and ERK1 and ERK2 mitogen-activated protein kinases, were
obligatory extracellular steps for the FasL-induced expression of a
subset of inflammatory mediators, including CXCL8/interleukin
(IL)-8, ICAM-1, IL-1, IL-1,CCL20/MIP-3, andthymicstromal
lymphopoietin. These results expand the knownphysiological role
of EGFR and its ligands from promoting keratinocytemitogenesis
and survival tomediating FasL-induced epidermal inflammation.
FasL,3 a member of the tumor necrosis factor family of cyto-
kines (reviewed in Ref. 1), signals apoptotic cell death by
engagement of its cognate receptor, Fas (2, 3). FasL/Fas triggers
apoptosis by activating the caspase family of proteases
(reviewed in Refs. 4 and 5). FasL plays an important role in the
effector function of cytotoxic T lymphocytes and also regulates
their homeostasis (3). Deficiencies in either FasL or Fas are
associated with autoimmune lymphoproliferative syndrome (a
hereditary condition characterized by the accumulation of
atypical lymphocytes and autoimmune manifestations) and
systemic lupus erythematosus (6, 7). FasL expression enables
the immunoprivileged state of the cornea and the testis (8, 9),
thus further underscoring the important role of this cytokine in
restricting autoimmune inflammation under normal homeo-
static conditions.
On the other hand, several laboratories, including ours, have
revealed the importance of FasL/Fas as a positive regulator of
pathological inflammation as well, particularly in inflammatory
diseases of the skin. Keratinocytes in the healthy human express
Fas, but not FasL (10). However, abnormal expression of lyti-
cally active FasL was found in keratinocytes of patients with
toxic epidermal necrolysis, suggesting that a suicidal keratino-
cyte reaction contributes to the pathogenesis of toxic epidermal
necrolysis (10). FasL/Fas signalingwas implicated in acute cuta-
neous graft versus host disease (11). More recently, FasL was
found to be involved in the pathogenesis of eczematous derma-
titides or eczemas (such as atopic dermatitis and allergic con-
tact dermatitis) (12–15). A common histopathological feature
of eczemas is the formation of exudative epidermal vesicles that
are disruptive to the normal barrier function of the skin.
Although vesicle formation in eczemas has been largely attrib-
uted to rupturing of keratinocyte attachments as a result of
intercellular edema (spongiosis) (Ref. 12 and references
therein), recent findings suggest that keratinocyte death plays a
major role in vesicle formation (12, 13). This keratinocyte death
appears to be apoptotic and to be mediated by FasL, deliv-
ered to the epidermis by infiltrating T lymphocytes and act-
ing on Fas expressed on the surface of keratinocytes (13).
Recently, expression of both FasL and Fas by epidermal kerati-
nocytes was proposed to characterize fixed drug eruptions (16)
and drug-induced maculopapular rashes (17). Finally, the Fas/
FasL apoptotic pathway was proposed to contribute to the
Leishmania major-induced cutaneous ulceration (18).
These findings clearly demonstrated the important role of
FasL in epidermal destruction in inflammatory skin diseases.
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Supplemental Material can be found at: 
However, whether FasL could directly trigger the inflammatory
process was not known. We demonstrated recently that FasL
elicits a pro-inflammatory reaction in human HaCaT keratino-
cytes and reconstructed human epidermis (RHE) by triggering
the expression of stress-responsive transcription factors,
inflammatory cytokines, chemokines, and the adhesion mole-
cule ICAM-1 (19). We demonstrated that oligomerization of
Fas was required both for apoptosis and for the inflammatory
gene expression and that caspase activity was essential for apo-
ptosis but dispensable for the inflammatory gene expression
(19). These results suggested that FasL was a pro-inflammatory
cytokine in eczemas. FasL stimulated the activity of the NF-B
transcription factor in HaCaT cells, and this activity was
required for the FasL-induced activation of inflammatory genes
(19). The requirement for NF-B suggested that the pro-in-
flammatory actions of FasL were dependent on transcriptional
gene activation.
In this work, we employed RHE to elucidate three novel
aspects of FasL-induced inflammation in the epidermis, name-
ly: (i) the importance of the proper organotypic stratification,
(ii) the inhibitory role of caspases, and (iii) the unexpected
involvement of the EGFR-ERK axis in the transcriptional
inflammatory responses to FasL in the epidermis.
EXPERIMENTAL PROCEDURES
RHE: Primary Human Epidermal Keratinocytes (Neonatal)
(HEKn) and Their Immortalized Derivatives—HEKn-E6/E7
were established andpropagated as described (20, 21). ForRHE,
we employed the method of Poumay et al. (22), with modifica-
tions as described in Ref. 19. RHEs were fixed in freshly made
4% p-formaldehyde, embedded in paraffin, and after sectioning
were processed for immunohistochemistry following the spe-
cific protocols recommended by the respective manufacturers
for each antibody.
siRNA-mediated Knockdown of ERK1 and ERK2 in RHE—
The siRNA oligonucleotides were synthesized by the Depart-
ment of Molecular Microbiology and Immunology Research
Core Facility (Oregon Health & Science University, Portland,
OR). Equimolar amounts of the complementary oligonucleo-
tides were annealed in annealing buffer (50mMTris-HCl, pH 8,
100 mM NaCl) by denaturing at 90 °C for 2 min followed by
incubation at 37 °C for 1 h. The siRNA sequences were as fol-
lows: nonspecific control, sense 5-CGAGUAGGCUUCGUG-
ACUUdTdT-3, antisense 5-AAGUCACGAAGCCUACUC-
GdTdT-3; ERK1, sense 5-GCCAUGAGAGAUGUCUACAd-
TdT-3, antisense 5-UGUAGACAUCUCUCAUGGCdTdT-
3, derived from Ref. 23; and ERK2, sense 5-GCUAGGAACU-
AUUUGCUUUdTdT-3, antisense
5-AAAGCAAAUAGUUCCUAGCdTdT-3.
RNA interference was performed as outlined schematically
in Fig. 8A and as described below. On Day (5), HEKn-E6/E7
were cultured in 10 ml of EpiLifemedium supplemented with
human keratinocyte growth supplement (HKGS) as per the
manufacturer’s instructions (Cascade Biologics, Portland, OR)
in 100-mm tissue culture dishes (Sarstedt, Newton, NC) to a
final confluency of 40% after 18 h of incubation at 37 °C/
5%CO2. On Day (4), the medium was replaced with 8 ml of
EpiLife-HKGS. Lipofectamine2000 reagent (Invitrogen) was
diluted to 20 g/ml in 1 ml of OPTIMEM-reduced serum
medium (Invitrogen) and incubated for 5 min at room temper-
ature. Annealed siRNA was diluted to 500 nM in 1 ml OPTI-
MEM medium and then mixed with 1 ml of dilute Lipo-
fectamineTM2000 for 20 min at room temperature. Two ml of
siRNA/reagent mixture was added to the 8 ml of EpiLife-
HKGS medium/plate. The cells were transfected with siRNA
(50nM final concentration of each annealed siRNA) for 48 h.On
Day (2), transfected cells were trypsinized and counted. The
cells were diluted in EpiLife-HKGS medium to a concentra-
tion of 1 106 cells/ml, and 0.5ml was plated perMillicell-PCF
0.4 -m culture plate insert (Millipore, Billerica, MA). Inserts
were placed in 6-well plates containing 2.5 ml of EpiLife-
HKGS medium supplemented with 1.5 mM CaCl2, 10 ng/ml
human recombinant keratinocyte growth factor (PeproTech,
Inc., Rocky Hill, NJ), and 50 g/ml ascorbic acid. On Day 0, the
RHEs were switched to differentiation as described previously
in Ref. 19 and used typically at Day 4 as depicted in Fig. 8.
Chemicals, Fc:FasL, Blocking Reagents, Growth Factors, and
Cytokines—All of the commonly used chemicals and EGF were
from Sigma. Caspase inhibitors (z-VAD-fmk and z-IETD-fmk),
UO126, SB203580, SP600125, and AG1478 were from Calbio-
chem. Fc:FasL has been described previously (24). The LA-1
antibody was from R & D Systems (Minneapolis, MN).
RNA Isolation, AffymetrixMicroarray, andQuantitative Real
Time RT-PCR (qRT-PCR)—These techniques were performed
as previously described in Ref. 19. The following additional
primers were employed here: CCL20/MIP-3 mature mRNA
forward, 5-CGAATCAGAAGCAGCAAGCA-3; CCL20/
MIP-3 mature mRNA reverse, 5-AGCATTGATGTCACA-
GCCTTCA-3; CCL20/MIP-3 primary transcript forward,
5-CCACCTCTGCGGCGAATCAGAAG-3; CCL20/MIP-3
primary transcript reverse, 5-CTTAGGGACCCCCAGTTG-
AGCTC-3; ICAM-1 primary transcript forward, 5-CATCT-
ACAGTAAGAAGGGGCAGGG-3; ICAM-1 primary tran-
script reverse, 5-TCGTCAGAATCACGTTGGGC-3; TSLP
mature mRNA forward, 5-CCGTCTCTTGTAGCAATCGGC-
3; and TSLPmature mRNA reverse, 5-GGCAGCCTTAGTTT-
TCATGGC-3. For the detection of primary transcripts by qRT-
PCR,3gof totalRNAwerereverse-transcribed in thepresenceof
SuperScript III and random hexamer primers (Invitrogen).
RESULTS
Identification of FasL-regulated Genes in RHE—To identify
genes activated by FasL in an epidermotypic context, we per-
formedAffymetrixmicroarray analyses onRNAextracted from
RHE 4 h after exposure to FasL. The analyses were performed
on HG-U133 Plus 2.0 GeneChip arrays, which interrogate over
47,000 human transcripts. Subsequent analysis identified 571
genes that were up-regulated at least 2-fold and 186 genes that
were up-regulated at least 3-fold after FasL (available online at:
www.ohsu.edu/cellbio/faculty/Iordanov_data/Farley_et_al_
(2007).xls). The data were analyzed with both EASE (25) and
L2L (26) software, which automate the process of biological
theme determination by analyzing the overrepresentation of
genes that belong to categories that are functionally and struc-
turally defined. Supplemental Tables S1 and S2 display the L2L-
generated hierarchical analyses of the genes whose mRNA
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abundance was increased at least 3-fold after FasL. Overrepre-
sented genes in the Biological Process categories were asso-
ciated with wound, chemotaxis, inflammatory, immune, and
stress responses (supplemental Table S1). The Molecular
Function categories associated with these genes were iden-
tified as cytokine, chemokine, and growth factor activities
(supplemental Table S2). EASE analysis produced similar
results (not shown). A selection of 37 FasL-induced genes in
the organotypic model is shown in supplemental Table S3.
We also analyzed the genes that were down-regulated in
response to FasL (supplemental Tables S4–S6). For this pur-
pose, we first excluded from the Affymetrix data all genes that
were categorized as “absent” or “marginally present” in the con-
trol (untreated) RHE group. We excluded, additionally, all
genes from the control group that displayed basal levels of
expression below 100 arbitrary Affymetrix units. Of the
remaining 985 genes, we selected those that were down-regu-
lated at least 2-fold by the FasL treatment (a total of 442
Affymetrix probe IDs; i.e. 45%). Of these, 287were annotated in
the public databases Entrez Gene (www.ncbi.nlm.nih.gov/
sites/entrez?db  gene) or Gene Cards (www.genecards.org).
The L2L overrepresentation analysis of these genes by biologi-
cal process and molecular function is shown in supplemental
Tables S4 and S5, respectively. In the biological process catego-
ries, FasL-repressed genes appear to be overrepresented in the
categories related to metabolic processes (including DNA,
RNA, and protein metabolism). By molecular function, genes
belonging to the categories peptidase, helicase, and kinase
activities were down-regulated by FasL. Supplemental Table S6
contains the 68 genes that were down-regulated at least 2-fold
by FasL and whose basal expression in the control RHE was the
highest (i.e. at least 1000 arbitrary Affymetrix units). The top
ranking FasL-repressed gene was the chemokine C-X-C motif
ligand 14 (CXCL14), whose expression was down-regulated
26-fold in the presence of FasL (see “Discussion”). Interest-
ingly, the ability of FasL to trigger the repression of CXCL14
was significantly attenuated in the presence of the pan-caspase
inhibitor z-VAD-fmk.
qRT-PCR was employed to investigate the temporal appear-
ance of a variety of FasL-up-regulated gene transcripts that
belonged to the molecular function categories identified as
overrepresented in our Affymetrix array analyses. The mRNAs
encoding transcription factors c-Fos, c-Jun, Egr1, and ATF3
displayed maximum increases in abundance 4 h after FasL
treatment; their levels declined thereafter (Fig. 1A). The
mRNAs encoding proinflammatory cytokines and chemokines
and the adhesion molecule ICAM-1 were activated maximally
between 2 and 6 h post FasL (specifically, 2 h for tumor necrosis
factor-, 4 h for ICAM-1, IL-1, CCL20/MIP-3, CXCL3/
GRO, CXCL1/GRO, and CXCL8/IL-8, and 6 h for TSLP),
with the exception of IL-1 (maximum at 12 h) (Figs. 1B and
2A). Previous studies from our laboratory have demonstrated
that exposure of monolayers of keratinocytes to FasL resulted
in the activation of the EGFR via the secretion of EGFR-binding
ligands (21). Whereas the mRNA encoding amphiregulin
(AREG) demonstrated a single transient peak of accumulation
(at 4 h),mRNAs encoding epiregulin (EREG) andheparin-bind-
ing EGF (HB-EGF) displayed a prominent transient peak at 4 h
and a delayed second wave of activation that occurred between
18 and 24 h post FasL (Fig. 2B). In contrast to mRNA encoding
the former EGFR-binding ligands, the mRNA for transforming
growth factor- was not induced more than 2-fold within the
first 12 h after FasL stimulation but became elevated at 18 and
24 h post FasL.
Epidermal Organotypic Context Is Essential for the Inflam-
matory Responses of Human Keratinocytes to FasL—Surpris-
ingly, treatment with FasL of either primary HEKn or immor-
talized (HEKn-E6/E7) keratinocytes in two-dimensional tissue
culture conditions resulted in the strong activation of the
immediate-early genes encoding transcription factors (c-Jun,
c-Fos, ATF3, and Egr1), as in Fig. 1A, but failed completely to
trigger the activation of genes encoding inflammatory media-
FIGURE1.Timecourseof FasL-inducedaccumulationofmRNAsencoding
transcription factors and inflammatory mediators in RHE. RHEs (14 days
after the differentiation switch) were treated with FasL (250 ng/ml) for the
indicated times as previously described (19) and then interrogated, using
qRT-PCR, for the levels of specific transcripts at 1, 2, 4, 6, 12, 18, and 24 h of
exposure to FasL. The data are presented as fold change relative to the corre-
sponding untreated control RHEs. Error bars, standard deviation from tripli-
cate qRT-PCRs. A, mRNAs encoding transcription factors. B, mRNAs encoding
inflammatory mediators.
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tors (such as cytokines and chemokines, as well as ICAM-1) or
EGFR-binding ligands (not shown). These experiments have
been repeated a number of times with identical outcomes. This
lack of proinflammatory gene response to FasL in cultured ke-
ratinocytes was not affected by variations of Ca2 levels or
choice of growth medium (e.g. Dulbecco’s modified Eagle’s
medium,with orwithout fetal calf serum) (not shown), suggest-
ing that the proper epidermotypic context (and not growth
conditions) was absolutely essential for the proinflammatory
response to FasL.
Transcriptional Regulation of FasL-induced mRNAs—To
investigate the FasL-induced accumulation of mRNAs encod-
ing inflammatory mediators at a level mechanistically and tem-
porarily closer to true transcriptional activation of the corre-
sponding genes, we determined the accumulation of selected
primary transcripts following FasL administration. To this end
we employed a randomhexamer-primedmethod of cDNA syn-
thesis and exon-intron border-specific primers for qRT-PCR.
As shown in Fig. 2, some of the primary transcripts tested
displayed kinetics of increase that preceded those of the cor-
responding mature mRNAs (best exemplified by CCL20/
MIP-3, Fig. 2A; and AREG, Fig. 2B, RNAs). These examples
suggest that FasL-induced elevation of the mRNAs encoding
inflammatory mediators and EGFR-binding ligands in RHEs
involves true transcriptional activation of the corresponding
genes. These analyses further permitted us to identify increased
levels of primary FasL-induced transcripts at later times (24 h)
after the addition of FasL (e.g. ICAM-1, Fig. 2A; and AREG and
HB-EGF, Fig. 2B). Interestingly, this delayed accumulation of
primary transcripts was not mirrored by a corresponding
increase in the levels of theirmaturemRNAs (Fig. 2), suggesting
a level of regulation of these genes that escapes detection when
RT-PCR is employed to detect levels of mature mRNA
transcripts.
Caspase Activity Is a Potent Antagonist of the Pro-inflamma-
tory Action of FasL in RHE—Because FasL is known to activate
proapoptotic pathways in keratinocytes and other cell types, we
set out to investigate the potential role of FasL-activated
caspases in regulating the expression of proinflammatory
mRNAs following exposure of RHEs to FasL. First, we asked
whether caspases were activated within the time frame of onset
and optimal expression of FasL-induced genes. RHEs treated
with FasL displayed processing of procaspase 8 into the p43/
p41 intermediate fragments and the p18 mature large subunit
as early as 2 h (Fig. 3A). The processing of caspase 8 was inhib-
ited by the caspase 8-specific inhibitor z-IETD-fmk (27, 28)
(Fig. 3A). The activation of caspase 8 was accompanied by a
small, but detectable, processing of the effector procaspase 3,
first to the p20/p19 intermediates and subsequently to the p17
mature large subunit of the active caspase 3 (Fig. 3A). Apoptotic
nuclei were not detectable at 4 h after FasL but became evident
by 24 h in the basal layers of FasL-treated RHEs (as shown by
hematoxylin and eosin staining; Fig. 3B). Basal layers of RHEs at
24 h (but not 4 h) post FasL also revealed positive immunore-
activity for active caspase 3 (Fig. 3B). These data demonstrate
that FasL engaged the apoptotic cascade as early as 2 h post
addition but that the morphological manifestation of apoptosis
was not yet evident within the time frame of onset and optimal
expression of FasL-induced genes (2–4 h).
We then employed either z-IETD-fmk or the pan-caspase
blocker z-VAD-fmk to investigate whether the engagement of
apoptotic cascades by FasL would modify the accumulation of
proinflammatory transcripts in response to FasL. Fig. 4 demon-
strates that the application of either z-IETD-fmk or z-VAD-
fmk resulted in a dramatic increase in expression of a variety of
transcripts that encode cytokines and chemokines. For exam-
ple, in the absence of caspase inhibitors, FasL triggered a 475-
fold (58) increase in the expression of TSLPmRNAat 4 h post
addition. However, in the presence of either z-IETD-fmk or
z-VAD-fmk, the FasL increased the abundance of TSLPmRNA
to 20,000- and 17,000-fold, respectively (Fig. 4A). Similarly, in
the absence of caspase inhibitors, FasL triggered a 11-fold
(2.6) increase in the expression of IL-6 mRNA at 4 h post
addition. In the presence of either z-IETD-fmk or z-VAD-fmk,
the IL-6mRNAwas increased by FasL to 1,721-fold (130) and
622-fold (21), respectively (Fig. 4A). In addition to these
quantitative differences, inhibition of caspases affected the
responsiveness to FasL qualitatively as well. For instance, FasL
alone failed to induce the expression of CCL5/RANTES
mRNA, but FasL in the presence of either z-IETD-fmk or
z-VAD-fmk caused a 15–25-fold increase in expression of the
CCL5/RANTES mRNA (Fig. 4A and Ref. 19). The potentiating
effect of caspase inhibitors on FasL-induced gene expression
patterns appeared biased in favor of inflammatory mediators.
For example, in the presence of z-IETD-fmk, FasL effected a
40-fold increase in TSLP mRNA and 160-fold increase in
IL-6 mRNA (Fig. 4A). By comparison, the addition of FasL
FIGURE 2. Time course of FasL-induced accumulation of primary tran-
scripts versus their corresponding mature mRNAs. Treatment and analy-
ses performed as for Fig. 1. Primary transcripts (dotted lines, y axes on the
right-hand side of the graphs) and mature mRNAs (filled lines, y axes on the
left-hand sideof the graphs) encodingCCL20/MIP-3 and ICAM-1 (A) or EGFR-
binding ligands (B). EREG appeared not to have introns and thereforewas not
suitable for primary transcript analyses.
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increased the expression of mRNA encoding EGFR-binding
ligands (AREG, HB-EGF, and EREG) only3-fold in the pres-
ence of z-IETD-fmk and even less in the presence of z-VAD-
fmk (Fig. 4B). Furthermore, FasL-induced transforming growth
factor- mRNA expression was not substantially increased by
either caspase inhibitor (Fig. 4B). In a similar fashion, the
potentiation of FasL-induced expression of the mRNAs encod-
ing the transcription factors c-Fos, c-Jun, Egr1, and ATF3 was
within the range of3-fold (Fig. 4C). The measurement of pri-
mary transcripts encoding CCL20/MIP-3 and ICAM-1 sug-
gested that the potentiating effect of caspase inhibitors on the
FasL-induced proinflammatory gene expression occurred at
the level of transcription (Fig. 4A).
ERK, JNK, and p38 MAP Kinases Contribute Nonredun-
dantly to the Inflammatory Responses of Human Keratinocytes
to FasL—We have previously found that FasL activated JNK,
p38, and ERK MAP kinases in monolayer cultures of human
keratinocytes (21). To investigate the contribution of MAPKs
in the inflammatory response triggered by FasL in RHE, we
applied specific inhibitors, singly and in combination, that are
FIGURE 3.Activation of caspases by FasL in RHE. A, RHEs were treated with
FasL as in Fig. 1 in the presence of either Me2SO (vehicle) or z-IETD-fmk (IETD,
50M), both administered 30minprior to FasL. Activation of caspases 8 and 3
was determined in immunoblot analyses. B, hematoxylin and eosin (H & E)
staining or immunohistochemical detection of active caspase 3 at either 4 or
24hafter treatmentwith FasL. Theexperimentswereperformedasdescribed
in Ref. 19. Examples of apoptotic cells, determinedbymorphology (hematox-
ylin and eosin staining) or the presence of active caspase 3, are identified by
single- or double-headed arrows, respectively. DMSO, dimethyl sulfoxide.
FIGURE 4. Effects of caspase inhibitors on the FasL-induced expressionof
inflammatory mediators (A), EGFR-binding ligands (B), or transcription
factors (C). RHEs were treated with FasL as in Fig. 1 in the presence of a
30-min pretreatment withMe2SO (vehicle, lanes) or 50M of either z-IETD-
fmk (lanes I) or z-VAD-fmk (lanes V). qRT-PCR analyses were performed 4 h
after FasL. The data are presented as fold change relative to the correspond-
ing untreated control RHEs. Error bars, standard deviation from triplicated
qRT-PCRs. Note that the qRT-PCR analyses of CCL20/MIP-3 and ICAM-1 RNA
expression were performed both for the primary transcripts and the mature
mRNAs.
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known to interfere with effective transduction of the ERK, JNK,
and p38 MAPK cascades: UO126, an inhibitor of MEK, the
upstream activator kinase for ERK; SP600125, a direct inhibitor
of JNK; and SB203580, a direct inhibitor of p38 MAPK. The
effectiveness and specificity of these inhibitors was confirmed
in immunoblot analyses using phospho-specific antibodies
against these kinases and/or their downstream phosphorylated
targets (data not shown). We investigated the effects of inhib-
iting MAPKs on the FasL-stimulated expression of various
mRNAs encoding proinflammatory mediators and EGFR-
binding ligands. The FasL-induced expression of all genes
tested was abolished in the presence of all three MAPK inhibi-
tors, suggesting that MAPK activity in general is essential for
FasL-induced mRNA expression (Fig. 5). Several FasL-induced
mRNAs (e.g. IL-1, IL-1, CCL20/MIP-3, and TSLP) were
strongly inhibited by each of the three MAPK inhibitors when
applied singly (Fig. 5), whereas other FasL-induced mRNAs
were dependent on one or two of theMAPKmembers for their
activation (Fig. 5). Taken together, these results suggest that the
ERK, JNK, and p38MAPKs are instrumental in a nonredundant
fashion in orchestrating the proinflammatory responses to FasL
in RHE. Furthermore, HB-EGF (Fig. 5), AREG, EREG (not
shown here), IL-1, IL-1, CCL20/MIP-3, TSLP, CXCL8/
IL-8, and ICAM-1 (Fig. 5) were identified as FasL-induced
mRNAs that displayed a strong dependence on the ERK family
of MAPKs.
Recruitment of EGFR to Mediate the ERK-dependent Inflam-
matory Responses to FasL—We further investigated the subset
of FasL-induced genes encoding growth factors and inflamma-
tory mediators whose induction by FasL displayed strong
dependence on the ERK family of MAPKs. We previously
reported that FasL triggers the activation of ERK MAPKs in
cultured human keratinocytes through stimulation of the auto-
crine secretion of soluble EGFR-binding ligands, one of which
we identified as AREG (21). To determine whether EGFR and
its ligands mediate FasL-induced pro-inflammatory responses
in RHEs, we first investigated whether FasL treatment would
trigger EGFR activation in the reconstructed epidermis in a
manner similar to the one observed in cultured keratinocytes.
Indeed, RHEs treated with FasL for 2 or 4 h displayed increased
phosphorylation of EGFR (Fig. 6, lanes 7 and 11). FasL-induced
EGFR phosphorylation was abolished in the presence of
AG1478, a small molecule inhibitor of the kinase activity of
EGFR (29) (Fig. 6, lanes 8 and 12). FasL also triggered the phos-
phorylation of p44 ERK1 and p42 ERK2 (Fig. 6, lanes 7 and 11),
and this phosphorylation was abrogated by AG1478 (Fig. 6,
lanes 8 and 12). FasL stimulated the phosphorylation of JNK
and p38 MAP kinases (Fig. 6, lanes 7 and 11), but in con-
trast to the phosphorylation of ERK, the phosphorylation of
JNK and p38 was not dependent on EGFR activity (Fig. 6,
lanes 8 and 12).
We next employed either AG1478 (at a low dose, 100 nM, to
minimize possible “off target” effects; Fig. 7A) or LA1, an EGFR-
neutralizing antibody (30–32) (Fig. 7B) to investigate the
potential contribution of EGFR to FasL-induced gene expres-
sion. Either mode of EGFR inhibition substantially suppressed
the FasL-induced activation of HB-EGF, IL-1, IL-1, CCL20/
MIP-3, CXCL8/IL-8, TSLP, ICAM-1 (Fig. 7), and AREG (not
shown) but not that of tumor necrosis factor-mRNA (Fig. 7).
We concluded, therefore, that part of the inflammatory action
of FasL was mediated through activation of the EGFR.
Contribution of Both ERK1 and ERK2 to the FasL-induced
Gene Expression—To assess the relative contributions of ERK1
and ERK2 to the FasL-induced pro-inflammatory gene expres-
sion, we developed a technique for siRNA-mediated gene
knockdown inRHEpreparations (outlined schematically in Fig.
8A). In the optimization phase, it appeared that a sustained
siRNA-mediated knockdown of various gene products could be
maintained for 4 days after the switch to organotypic differ-
entiation (Fig. 8A). To assess how early organotypic recon-
structs develop epidermal characteristics, we measured barrier
function and the expression of differentiation markers. RHEs
established proper barrier function by day 3 after the switch to
FIGURE 5. Effects of MAP kinase inhibitors on the expression of FasL-in-
duced genes. RHEs were treated with FasL as in Fig. 1 in the presence of
30-min pretreatments with either Me2SO (vehicle,) or various antagonists
as labeled.UO, UO126, 10M; SB, SB203580, 10M; SP, SP600125, 40M;All, all
three inhibitors together. qRT-PCR analyses were performed 4 h after FasL.
The data are presented as fold change relative to the corresponding vehicle-
treated control RHEs. Error bars, standarddeviation fromtriplicatedqRT-PCRs.
FIGURE 6. Activation of EGFR and MAP kinases in RHE. RHEs were treated
with FasL (FL) as in Fig. 1 in the presence of 30-min pretreatments with either
vehicle (Me2SO, lanes ) or AG1478 (10 M, lanes AG). The phosphorylated
states of EGFR and MAP kinases were assessed using phospho-specific anti-
bodies at the indicated times. Treatmentwith EGF (lanes E, 100 ng/ml) served
as positive control. Immunoblot detections of total ERK1/2 and p38 MAPK
were used to monitor for expression levels and equal loading.
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differentiation (Fig. 8B), and when
examined at day 4, they displayed
mature epidermal stratification,
including the presence of stratum
corneum and proper expression of
keratin 1 (Fig. 8B, inset). For these
reasons, the experiments described
below were performed using RHEs
at day 4 after the initiation of differ-
entiation. RHEs that were subjected
to a double knockdown of ERK1 and
ERK2 (Fig. 9) showed a pattern of
epidermal differentiation that was
similar to control RHEs (supple-
mental Fig. S1). However, the dou-
ble knockdown cultures exhibited a
slightly delayed onset of differentia-
tion, manifested by the decreased
thickness of the stratum corneum
(supplemental Fig. S1), a weaker
(but properly stratified) keratin 1
immunoreactivity (supplemental
Fig. S1), and a 2-fold decrease in
barrier function (Fig. 8C).
Fig. 9 shows the effect of knocking down ERKMAPKs on the
FasL-induced expression of CXCL8/IL-8. As expected from the
previous findings using UO126 (Fig. 5), reducing the levels of
both ERK1 and ERK2 in two independent experiments inhib-
ited the responsiveness of CXCL8/IL-8 to FasL by 87 and 90%,
respectively. It appeared that both ERK1 and ERK2 contributed
to the activation of CXCL8/IL-8 by FasL, because single knock-
downs of either kinase caused only partial inhibition of CXCL8/
IL-8 expression (Fig. 9). Similar outcomes were observed for
CCL20/MIP-3a, ICAM-1, andTSLP (not shown). The degree of
siRNA-mediated effects on FasL-induced gene expression
appeared to correlate with the achieved efficiency of knock-
down of a targeted protein (compare, for instance, the knock-
down of ERK1 in the two experiments presented in Fig. 9).
These results strongly support the notion that both ERK1 and
ERK2 contribute to the genomic responses to FasL.
DISCUSSION
Apoptosis and Inflammation in the Skin—The studies pre-
sented here and recently (12–14, 21, 33) have been directed
toward uncovering the possible roles of FasL and apoptosis in
human eczema. Eczema is traditionally thought of as disease
characterized primarily by inflammatory phenomena. How-
ever, apoptosis of keratinocytes is a key hallmark of the acute
eczematous epidermis and is thought to play an important role
in spongiosis and vesicle formation in dermatitis (12–14, 21,
33). FasL appears to be the most prominent candidate for the
mediation of keratinocyte apoptosis in dermatitis (12–14, 21,
33). Neither apoptosis nor spongiosis characterizes the epider-
mal lesion in psoriasis, another skin disease that is inflamma-
tory, but not eczematous (34). Thus, apoptosis is a defining
feature specifically of the eczematous type of tissue inflamma-
tion. One important question from a clinical point of view is
whether attempts to suppress keratinocyte apoptosis in the epi-
FIGURE 7. Effects of EGFR antagonists on the expression of FasL-induced genes. RHEs were treated with
FasL as in Fig. 5 in the presence of 30 min pretreatments with either AG1478 (A, lanes AG, 100 nM) or LA-1
antibody (B, lanes LA, 10g/ml). qRT-PCRanalyseswereperformed4hpost FasL. Thedata arepresentedas fold
change relative to the corresponding vehicle-treated control RHEs. Error bars, standard deviation from tripli-
cated qRT-PCRs. FL, FasL.
FIGURE8.A, efficient siRNA-mediated knockdownof ERK2 at day 4 after the
switch to differentiation. HEKn-E6/E7 were transfected with the indicated
siRNAs, plated, and differentiated into RHEs as depicted in the experimental
scheme. Immunoblot analysis with an antibody against ERK1 and ERK2 (pan-
ERK antibody). ERK1 serves as a loading and specificity control. B, proper bar-
rier function, morphology, and keratin 1 expression of RHEs at day 4 after the
switch to differentiation. “Outside-In” barrier function was assessed by Tolu-
idine Blue O dye penetration assay, and it is presented as a percentage of
permeability relative to the permeability of the reconstructs immediately
after the initiation of differentiation (Day 0). Insets, epidermal morphology
(hematoxylin and eosin staining,H& E) and detection of keratin 1 (K1) expres-
sion. C, effect of double knockdownof ERK1 and ERK2 on the barrier function.
Note that the decrease of barrier function (i.e. increase in permeability) after
the knockdown of ERK is small compared with the range of permeability
decreaseoccurringduringnormal epidermal differentiation (dotted lines con-
necting B and C).
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dermiswould be beneficial to dermatitis patients. Alternatively,
apoptosis could be part of the “healing” process that serves the
purpose to restrict uncontrolled inflammation, even at the
price of temporary tissue damage. Our findings presented here
suggest that therapeutic strategies aimed at epidermal apopto-
sis suppression at the level of caspase activity may prove detri-
mental by aggravating inflammation (see below).
Positive and Negative Regulation of Gene Expression by FasL—
The unbiased approach to gene expression analysis offered by
microarray technologies allows for the identification of both
positively and negatively regulated genes in experimental sys-
tems of interest. Although the main body of work presented
here deals with genes that were induced by FasL in RHE, the
Affymetrixmicroarray analysis revealed that a substantial num-
ber of RNA transcripts (as high as 45%, see “Results”) was
reduced in abundance 4 h after FasL administration. Aminority
(12%) of the 287 annotated repressed genes considered in our
analysis was affected more than 3-fold. Of the 68 FasL-down-
regulated transcripts selected for their high basal expression in
untreated RHE (supplemental Table S6), also 12% (i.e. the eight
transcripts labeled in red in supplemental Table S6) were
down-regulated more than 3-fold. The chemokine CXCL14,
whose expression was reduced 26-fold after FasL, may be of
particular interest for further investigation. The relatively high
levels of CXCL14mRNAexpression in our RHE (1182 arbitrary
Affymetrix units, see primary data available online at www.ohsu.
edu/cellbio/faculty/Iordanov_data/Farley_et_al_(2007).xls)
are in agreement with the findings of Moser and co-workers
(35, 36), who reported high constitutive levels of CXCL14
expression in healthy human epidermis and in RHE.
Recently, the same research group reported evidence
strongly supporting a critical role for cutaneous CXCL14 in
targeting blood precursors of dendritic cells to the epidermis
for their differentiation as Langerhans cells (36). Because
CXCL14 appears to act in a constitutive manner under non-
inflammatory conditions, the authors suggested that
CXCL14 might play a role in the steady-state functions of
dendritic cells such as presentation of self-antigens for the
purpose of elimination of self-reacting T cells and/or induc-
tion of suppressor/regulatory T cells (36). It is therefore
tempting to speculate that FasL affects the genomic
responses of epidermal keratinocytes by both inducing pro-
inflammatory chemokines (e.g. CCL20, CXCL1–3, and
CXCL8) and repressing, simultaneously, the expression of a
potentially “anti-inflammatory” chemokine, CXCL14.
Pro-inflammatory Actions of FasL in Human Keratinocytes:
Importance of the Organotypic Context—As described here and
in Ref. 19, a single trigger, FasL, reproduces key clinical and
molecular hallmarks of the eczematous epidermis in RHE.
However, the inflammatory genomic responses to FasL
observed in RHEs are in stark contrast to the lack of the same
responses under two-dimensional tissue culture conditions. In
vitro tissue culture has been employed previously to study the
behavior of the eczematous keratinocyte. For instance, cultured
keratinocytes from patients with atopic dermatitis display
abnormal responses to T cell-derived cytokines (37, 38). How-
ever, the inappropriate genomic responses of cultured kerati-
nocytes to FasL observed by us underscore the limitations of the
tissue culture in studying eczemas. Ironically, the pro-inflam-
matory potential of FasL in human keratinocytes was initially
discovered in the keratinocyte cell line HaCaT (19). We were
therefore surprised to observe the complete lack of inflamma-
tory gene expression in FasL-treated primary keratinocyte
explants (HEKn) or in their immortalized derivatives, HEKn-
E6/E7. However, the same HEKn or HEKn-E6/E7 when grown
in an epidermotypic context (RHE) “regained” the ability to
respond to FasL with increased expression of inflammatory
mediators. As far as we have been able to determine, the main
reason for this different behavior is the inability of HEKn or
HEKn-E6/E7 in tissue culture to respond to FasL with activa-
tion of NF-B (not shown).4 In contrast, HaCaT cells in tissue
culture potently activate NF-B in response to FasL (19).
Indeed, siRNA-mediated knockdown of the p65/RelA subunit
inHaCaT (19) or inHEKn-E6/E7RHEs (not shown)4 abrogated
the FasL-triggered expression of inflammatory mediators. It
should be emphasized that HEKn and HEKn-E6/E7 in tissue
culture display normal NF-B activation in response to cyto-
kines other than FasL (e.g. tumor necrosis factor-, or IL-1;
not shown).4 Furthermore, HEKn and HEKn-E6/E7 in tissue
culture display an efficient response to FasL as determined
by apoptosis (21) or expression of NF-B-independent genes
(such as c-fos or c-jun; not shown).4 Therefore, it is reason-
able to conclude that HEKn and HEKn-E6/E7 in tissue cul-
4 S. M. Farley, D. E. Purdy, O. P. Ryabinina, P. Schneider, B. E. Magun, and M. S.
Iordanov, manuscript in preparation.
FIGURE9. siRNA-mediatedknockdownofERK1,ERK2,orboth, inRHEand
the effect of the knockdown on the expression of CXCL8/IL-8. RHEs were
transfected in two independent experiments with the indicated siRNAs
(scram, “scrambled” control siRNA; for Experiment 2, E1 denotes ERK1, and E2
denotes ERK2) and analyzed at day 4 post the differentiation switch as
described in the text and in Fig. 8A. The top panels depict immunoblot detec-
tions of ERK1, ERK2, and p38 MAP kinases. p38 MAPK is used as control for
siRNA specificity and loading control. The bottom panels depict the expres-
sion of CXCL8/IL-8 mRNA 4 h after FasL treatment was determined by qRT-
PCR at day 4 after the differentiation switch. The data are presented as fold
change relative to the corresponding untreated control RHEs. Error bars,
standard deviation from triplicated qRT-PCRs. The percentage of change rel-
ative to scrambled siRNA is indicated.
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ture are specifically deficient in the proinflammatory genomic
responses to FasL and that epidermotypic context (RHE)
restores these responses. Because keratinocytes in tissue cul-
ture most resemble the undifferentiated transit-amplifying
cells in the basal layer of the epidermis, it is tempting to specu-
late that the cells responding to the pro-inflammatory actions
of FasL in RHEs are not the basal keratinocytes but rather ke-
ratinocytes within the strata spinosum or granulosum. Presum-
ably,HaCaT cells differ fromHEKn andHEKn-E6/E7 by having
either gained a positive, or having lost a negative, FasL-trig-
gered regulator of NF-B.
Possible Anti-inflammatory Functions of Caspases—Our
results using the caspase inhibitors z-IETD-fmk and z-VAD-
fmk (Fig. 4) strongly support the notion that caspase activity
may have the physiological role of limiting the extent of FasL-
triggered inflammation in the skin. Initially, we considered the
simplest explanation, namely that caspases limit the inflamma-
tory response by promoting cell death. By means of rapid elim-
ination of FasL-challenged keratinocytes, the extent of tran-
scriptional activation and release of inflammatorymediators by
the same cells would be restricted. Although this explanation
cannot be ruled out, it does not fully concur with the experi-
mental observations. As Figs. 1 and 2 demonstrate, the peak of
inflammatory gene expression occurs within 4 h after the
administration of FasL. At this time, the caspase activity,
although clearly detectable (Fig. 3), is well below the levels
observed at later time points (Fig. 3B). Importantly, at 4 h after
FasL, keratinocytes in the RHEs display normal morphological
characteristics (Fig. 3B, panels I and II). Nuclear pyknosis, kary-
orrhexis, and cell swelling were only observable at later times
(e.g. 24 h; Fig. 3B, panel VI). We have also reported previously
that HaCaT cells, treated with FasL for up to 4 h and displaying
75% cleaved poly(ADP-ribose) polymerase, nevertheless
maintain high levels of biosynthetic activity, as determined by
incorporation of [3H]leucine into newly synthesized proteins
(19). Taken together, these findings argue against the conclu-
sion that caspases limit FasL-triggered inflammation by simply
eliminating inflammatory cytokine-producing cells. We pro-
pose an alternative hypothesis, i.e. that the initial activation of
caspases triggers an active anti-inflammatory program before
the onset of cell death. Such an early action of caspases would,
therefore, define a novel function for these proteases, a function
that is kinetically separable from their cytotoxic properties. The
anti-inflammatory functions of caspases may be effected, for
instance, through suppression of the FasL-triggered activation
of NF-B, a possibility being currently investigated.
One clinically relevant conclusion from these findings might
be that attempts to suppress keratinocyte apoptosis bymeans of
caspase inhibition in acute dermatitis may have the unintended
consequences of aggravated inflammatory response and, ulti-
mately, a worse outcome for the patient. An important unan-
swered question that remains is whether the anti-inflammatory
signals associated with activated caspases are effected directly
by the apical caspases 8 and 10 or further downstream by effec-
tor caspases such as caspases 3 and 7. Should the anti-inflam-
matory functions be specific for the apical caspases only, strat-
egies aimed at inhibiting effector caspases may be beneficial in
limiting apoptosis, yet avoiding aggravated inflammation.
A Novel Role of the EGFR-Ras-ERK Cascade in Mediating
Inflammation in the Skin—We have previously reported that
the basal levels of ERK activity in HEKn or HEKn-E6/E7 in
tissue culture were determined by the autocrine secretion of
ligands that bind to the EGFR (20). Interfering with either the
extracellular ligand-binding portion of EGFR by means of the
LA-1 antibody or the intracellular kinase domain of EGFR
reduced the basal phosphorylation of ERK1 and ERK2 to unde-
tectable levels (20). We have also reported that FasL-induced
ERK activation of HEKn or HEKn-E6/E7 in culture is mediated
by FasL-simulated secretion of EGFR ligands (one of which was
identified as amphiregulin) and the subsequent activation of
EGFR (21). FasL also activated EGFR inRHEs (Fig. 6), and inter-
fering with the activity of EGFR prevented FasL-triggered acti-
vation of ERK (Fig. 6). A subset of FasL-induced inflammatory
mediators in RHEs was found to require ERK activity (Fig. 6).
Taken together, these findings had allowed us to predict that
EGFR would be recruited to mediate some of the inflammatory
gene expression in response to FasL in the RHE. This was
indeed found to be the case (Fig. 7). However, it should be
emphasized that the biological roles of EGFR in human skin are
likely to be much more complex than can be appreciated with
the available tools for experimentation. For instance, CXCL8/
IL-8, an EGFR-dependent, FasL-induced, potent inflammatory
mediator, is also a suspected keratinocytemitogen (39). Bearing
in mind that FasL triggers the production of mitogenic EGFR
ligands in human keratinocytes (21), it is likely that the physio-
logical outcomes of the presence of FasL in the human epider-
mis may be determined by the interplay of three seemingly dis-
parate phenomena: apoptosis, inflammation, and mitogenesis
(the last two being, at least partially, dependent on EGFR).With
the exception of the findings that anti-EGFR-directed therapies
of cancer produce cutaneous acne-like rashes as side effects
(40), our understanding of the roles of EGFR in the human skin
is still very limited.
The Roles of ERK1 and ERK2 in the Genomic Responses of
Keratinocytes to FasL—We report here that both ERK1 and
ERK2 are involved in mediating the proinflammatory gene
expression in response to FasL (Fig. 9). A single siRNA-medi-
ated knockdownof either ERK1or ERK2 reduced FasL-induced
CXCL8/IL-8 expression significantly, but a double knockdown
appeared necessary to reduce CXCL8/IL-8 expression by more
than 85% (Fig. 9). Recently, Vantaggiato et al. (41) presented
evidence that ERK1 and ERK2 play opposing roles inmediating
the proliferative effects of mitogenic growth factors and Ras-
driven oncogenic transformation. According to this model,
ERK2 mediates the proliferative and transforming effects of
activated Ras, whereas ERK1 inhibits these effects by compet-
ing with ERK2 for their mutual upstream activator MEK (41,
42). Interestingly, CXCL8/IL-8 expression was recently
reported to be a transcriptional target of Ras signaling (43), and
based on these findings, our initial expectations were that we
would observe opposing roles of ERK1 and ERK2 in mediating
the expression of CXCL8/IL-8 in FasL-treated RHEs. The fact
that this was not the case (Fig. 9) underscores the complexity of
MAPK regulation and function and strongly emphasizes the
need to investigate MAPK signaling pathways in the context of
specific tissues and organs. In conclusion, the RHE-based orga-
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notypic model described here could be applicable to study
pharmacologic manipulations of the FasL-driven genomic
responses as novel therapeutic options for the treatment of der-
matitis and other inflammatory skin conditions.
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